Trial Profile
Imatinib mesylate treatment of severe chronic GVH scleroderma-like refractory to conventional immunosuppressive therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2011
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Graft-versus-host disease; Scleroderma
- Focus Adverse reactions; Therapeutic Use
- 01 Sep 2011 New trial record